abstract |
Provided are a therapeutic agent and a method for treating urinary cancer, in particular, a urinary cancer in which the function of lysine (K)-specific demethylase 6A (KDM6A) is reduced, characterized in that it inhibits both IL-6 activity and CCR2/CCL2 activity. |